A61K 9/5026
Obtained by reactions only involving carbon-to-carbon unsaturated bonds
Official title: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
A61K9/5026 (Obtained by reactions only involving carbon-to-carbon unsaturated bonds) appears on 1,524 US grants and 2,480 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,524
- Published applications
- 2,480
- Assignees
- 987
- Inventors
- 3,898
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 3 | 0 |
| 1980 | 7 | 0 |
| 1981 | 0 | 0 |
| 1982 | 6 | 0 |
| 1983 | 1 | 0 |
| 1984 | 4 | 0 |
| 1985 | 1 | 0 |
| 1986 | 5 | 0 |
| 1987 | 9 | 0 |
| 1988 | 11 | 0 |
| 1989 | 16 | 0 |
| 1990 | 13 | 0 |
| 1991 | 10 | 0 |
| 1992 | 13 | 0 |
| 1993 | 18 | 0 |
| 1994 | 21 | 0 |
| 1995 | 14 | 0 |
| 1996 | 16 | 0 |
| 1997 | 19 | 0 |
| 1998 | 17 | 0 |
| 1999 | 16 | 0 |
| 2000 | 17 | 0 |
| 2001 | 27 | 13 |
| 2002 | 24 | 41 |
| 2003 | 46 | 77 |
| 2004 | 18 | 73 |
| 2005 | 16 | 86 |
| 2006 | 25 | 77 |
| 2007 | 14 | 92 |
| 2008 | 11 | 94 |
| 2009 | 14 | 81 |
| 2010 | 29 | 112 |
| 2011 | 23 | 90 |
| 2012 | 46 | 87 |
| 2013 | 59 | 97 |
| 2014 | 82 | 132 |
| 2015 | 70 | 145 |
| 2016 | 79 | 153 |
| 2017 | 84 | 152 |
| 2018 | 84 | 107 |
| 2019 | 88 | 133 |
| 2020 | 81 | 118 |
| 2021 | 83 | 102 |
| 2022 | 55 | 111 |
| 2023 | 50 | 77 |
| 2024 | 74 | 107 |
| 2025 | 67 | 65 |
| 2026 | 35 | 58 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Prolonged-release pharmaceutical composition for oral administration of sultiame6 Oct 2026US 12,751,928 B2Advicenne
- Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics8 Sep 2026US 12,728,110 B2Flamel Ireland Limited
- Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof28 Jul 2026US 12,691,074 B2Impax Laboratories, LLC
- Pulsed release caffeine formulations and a process for preparation thereof14 Jul 2026US 12,678,409 B2OmniActive Health Technologies Limited
- Poly[alpha-cyanoacrylate] hydrolyzate and preparation method and application thereof14 Jul 2026US 12,679,910 B2Dalian Heyuan Medical Equipments Co., Ltd.
- Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof1 Oct 2026US 2026/0294817 A1Impax Laboratories, LLC
- Microcapsules and encapsulation thereof24 Sep 2026US 2026/0283914 A1S H Kelkar and Company Limited
- Enriched Withania somnifera Based Dietary Composition and a Method Thereof24 Sep 2026US 2026/0284137 A1Arjuna Natural Private Limited
- Oral pharmaceutical compositions of dabigatran etexilate17 Sep 2026US 2026/0272904 A1Breckenridge Pharmaceutical, Inc.
- Niraparib formulations10 Sep 2026US 2026/0263441 A1Tesaro, Inc.
Most cited
By later US patents
- Controlled release formulations coated with aqueous dispersions of acrylic polymers1,011US 5,639,476 AEuro-Celtique S. A. · 1997
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Gels for encapsulation of biological materials587US 5,858,746 ABoard of Regents, The University of Texas System · 1999